Statement of Principles concerning polycythaemia vera (Reasonable Hypothesis) (No. 87 of 2021)

The instrument’s principal concepts are its working definition of polycythaemia vera, the qualifying factors that may link the disease to relevant service, and the required relationship between those factors and service. The definition in subsection 7(2) establishes the biological and clinical scope of the disease for these claims. It treats polycythaemia vera as a chronic Philadelphia‑chromosome negative myeloproliferative neoplasm characterised by proliferation of bone marrow cells of all types and elevated red cell production, with usual excess of platelets and white blood cells (s7(2)(a)). The definition expressly includes masked or bled down presentations (s7(2)(b)), and expressly excludes relative, familial and congenital forms and secondary polycythaemia due to hypoxaemia or increased erythropoietin (s7(2)(c)(i)-(iii)). The instrument notes the ICD‑10‑AM code D45 but specifies that the meaning for claims is the statutory definition in s7(2) (s7(3)-(4)).

A core operational concept is the “factor” approach. Section 9 lists the factors that must exist, at minimum, for a reasonable hypothesis to be raised. Two discrete factors are identified. The first (s9(1)) is having smoked tobacco products at a cumulative exposure of at least 10 pack‑years, with smoking commencing at least five years before clinical onset of polycythaemia vera, and if smoking ceased prior to clinical onset, the onset must have occurred within 15 years of cessation. The instrument defines “one pack‑year” and gives conversion and calculation guidance in the Schedule 1 dictionary (one pack‑year equals smoking 20 cigarettes per day for 1 year, with equivalent weight measures supplied) and provides examples of pack‑year computation (Schedule 1). The second qualifying factor is inability to obtain appropriate clinical management for polycythaemia vera (s9(2)).

The instrument distinguishes the types of relationship to service required. Section 10(1) requires that any factor in s9 must be related to the person’s relevant service. Section 10(2) limits the application of s9(2) (inability to obtain appropriate clinical management) to material contribution to, or aggravation of, polycythaemia vera where the disease was suffered or contracted before or during relevant service but did not arise out of service. Thus the management factor is not a standalone cause of initial disease in the case where the disease first arose out of service; instead it is available for claims alleging material contribution or aggravation where the condition pre‑dated or began during service (s10(2)).

The instrument also contains cross‑reference mechanics. If a factor in s9 refers to an injury or disease that is the subject of another Statement of Principles made under subsection 196B(2) of the VEA, then the factors in that other Statement apply in accordance with their terms as in force from time to time (s11). The Schedule provides definitions used throughout, including “relevant service”, “terminal event”, MRCA and VEA, and clarifies the pack‑year conversion (Schedule 1).

This Statement of Principles affects persons making claims under the VEA or MRCA for polycythaemia vera or death from polycythaemia vera, and those who assess those claims. The instrument explicitly applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (s5). The Schedule defines “relevant service” to encompass operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA (Schedule 1). Therefore, veterans, members of Peacekeeping Forces, and members of the Forces who rendered any of those types of relevant service are within the persons affected by the Statement (s8 records the Repatriation Medical Authority’s view that polycythaemia vera can be related to relevant service).

Who pays and who decides in practical terms is governed by the administering statutes rather than this Statement. The instrument itself does not set out compensation amounts, administrative steps, or payment mechanisms. What it does structure is the medical threshold for raising a reasonable hypothesis that the condition is connected to service, which is the medical input decision makers will use when deciding entitlement under the VEA or MRCA. Decision makers, claimants and medical advisers will need to apply the instrument’s definitional and factor tests when compiling or reviewing evidence for claims under the statutory provisions referenced in s5.

The Statement affects medical practitioners asked to provide medico‑legal reports because it sets out specific clinical definitions and temporal thresholds the Repatriation Medical Authority regards as relevant. For example, practitioners will need to record whether the condition fits the statutory definition in s7(2), whether it is masked or bled down (s7(2)(b)), and whether the claimant’s smoking history meets the pack‑year and timing criteria in s9(1) and Schedule 1. Clinical evidence on the availability of “appropriate clinical management” is relevant where s9(2) is relied upon, and the instrument limits that factor’s application to situations described in s10(2).

Finally, the instrument affects legal and advocacy representatives preparing claims or appeals, because reliance on a factor in s9 will require establishing a relationship to relevant service per s10. Where a factor in s9 refers to a disease already the subject of another Statement of Principles, claimants and advisers must follow that other Statement as it reads from time to time (s11). The Statement does not itself adjudicate disputes, but it sets the medical threshold and definitions that tribunal or administrative decision makers will apply when considering entitlement claims brought under the VEA or MRCA.

The instrument establishes duties of proof and rights in the limited sense that it sets the minimum medical factors that must exist to raise a reasonable hypothesis linking polycythaemia vera to relevant service. It does not establish criminal or civil liabilities, monetary obligations, or procedural rights; those are contained in the VEA and MRCA. The Statement places the following legal effects and operational duties on claimants and decision makers.

Claimants must, if they wish to rely on the factors in section 9, produce evidence satisfying those elements. For smoking, evidence must demonstrate a cumulative exposure of at least 10 pack‑years, that smoking commenced at least five years before clinical onset, and if smoking ceased before clinical onset, that onset occurred within 15 years of cessation (s9(1)). The Schedule explains how pack‑years are calculated and gives a weight equivalent for non‑cigarette tobacco products (Schedule 1). For the inability to obtain appropriate clinical management factor (s9(2)), evidence will need to show what clinical management was appropriate and that it was unavailable; the instrument then restricts that factor’s application as to temporal relationship with service in s10(2).

Decision makers applying this Statement have the duty to treat the statutory definitions and factors as the Repatriation Medical Authority’s established medical framework for reasonable hypothesis assessment. Section 8 records that the Authority is of the view that there is sound medical‑scientific evidence indicating polycythaemia vera can be related to relevant service, which is the evidentiary basis for the Statement. Decision makers must therefore assess whether the statutory definition in s7(2) is met, whether at least one of the factors in s9 exists, and whether that factor is related to relevant service under s10, when applying the VEA or MRCA sections specified in s5.

There is a procedural duty implicit in s11 where a factor refers to an injury or disease covered by another Statement of Principles: the applicable terms of the other Statement apply in accordance with their wording as in force from time to time. Therefore, parties must be aware of the current text of any cross‑referenced Statement because that will shape the analysis when such factors arise.

The Statement creates a right for claimants in conceptual terms: if the statutory definition and the factors and relationship to service are satisfied, then a reasonable hypothesis has been raised connecting the disease or death to service. That, in turn, is the medical threshold that supports entitlement processes under the VEA or MRCA. The Statement does not itself create procedural remedies or determine final entitlement; it supplies the medical standard to which claimant evidence must conform for decision makers to accept a connection to service.

The instrument contains no penal provisions and does not establish enforcement mechanisms or sanctions. Its legal effect is normative rather than punitive. It is a Statement of Principles made under subsection 196B(2) of the VEA (s3), intended to be used as the medical‑scientific framework for assessing whether a reasonable hypothesis has been raised linking polycythaemia vera to relevant service in claims covered by section 120A of the VEA or section 338 of the MRCA (s5). Nothing in the instrument prescribes criminal penalties, administrative fines, or enforcement actions for non‑compliance by claimants or medical practitioners.

Enforcement, in the sense of how the Statement is applied, is administrative: it will inform decision makers under the VEA and MRCA when considering claims. The instrument itself does not outline appeal routes, sanctions for false claims, or investigative procedures. Any investigation, verification or adverse finding related to a claim based on this Statement would proceed under the procedural and enforcement provisions of the VEA, MRCA, or other statutes and regulations governing those claims, which are not contained within this instrument. The instrument simply sets the medical criteria that decision makers should use to determine whether a reasonable hypothesis exists; subsequent administrative consequences (acceptance, rejection, entitlement assessment) are then governed by the primary legislation and associated procedures.

Because the Statement repeals a prior Statement (s4), its practical effect on previously made or pending claims depends on the application rules of the VEA and MRCA and any transitional arrangements in those statutes or administrative practice. The instrument does not itself set transitional penalties or retrospective enforcement measures. In short, the instrument does not create or describe enforcement mechanisms or penalties; it supplies medical criteria for application by the statutory decision makers referenced in s5, and enforcement questions are to be answered by the administering statutes and their processes.

This Statement is expressly made under subsection 196B(2) of the VEA (s3) and applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (s5). The instrument therefore operates as a subordinate, medical‑scientific input to claims under those primary Acts. It does not alter the substantive entitlements, procedural steps, or remedial architecture of the VEA or MRCA, but it defines the medical conditions and factors that decision makers must use to decide whether a reasonable hypothesis has been raised linking polycythaemia vera or death from polycythaemia vera to relevant service.

When a factor in section 9 refers to an injury or disease that is the subject of another Statement of Principles determined under subsection 196B(2) of the VEA, section 11 requires that the factors in that other Statement apply in accordance with its terms as in force from time to time. This creates a direct legal cross‑reference mechanism within the family of Statements of Principles, and means that the effective medical test for some factors can change as other Statements are amended or replaced (s11). Administrative actors and claimants therefore must consult the current text of relevant cross‑referenced Statements when compiling or adjudicating evidence.

The instrument also interacts with diagnostic coding systems only to the extent that it mentions the ICD‑10‑AM code D45 as a cross‑reference while clearly stating the statutory meaning for claims is that provided by s7(2) (s7(3)-(4)). The ICD code is referenced as an identifier but the statutory definition governs in the event of any divergence.

Definitions in the Schedule link the Statement to the concepts used in the primary Acts. The Schedule defines “relevant service” to include operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA (Schedule 1). The inclusion of MRCA and VEA as defined terms connects the Statement’s medical framework directly to the scope of service types enumerated in the primary legislation.

Because the instrument does not itself contain procedural rules, penalties, or entitlement formulae, its interaction with other laws is confined to guiding the medical assessment stage of claims under the VEA and MRCA. Any procedural, evidential, or remedial consequences are determined by those Acts and subordinate instruments made under them, which are not reproduced within this Statement. The repeal of the prior Statement (s4) replaces the earlier medical framework for polycythaemia vera with the provisions of this instrument as of its commencement date (s2).

The instrument records a single express amendment action within its own text. Section 4 repeals the previous Statement of Principles concerning polycythaemia vera No. 11 of 2013 (Federal Register of Legislation No. F2013L00404). The commencement date of the current instrument is 20 September 2021 (s2) and it is dated 20 August 2021 on its face. The instrument is identified as Statement of Principles concerning polycythaemia vera (Reasonable Hypothesis) (No. 87 of 2021) (s1). No other amendments, historic versions, or amendment timelines are included in this instrument.

The Schedule’s definitions supply conversion rules and clarifications that are part of the operative text and therefore part of the instrument as made. For example, the definition of “one pack‑year” and the explanatory notes about equivalent tobacco quantities and calculation examples are integral to how the smoking factor in s9(1) will be applied. Any future amendment to the Schedule or to any cross‑referenced Statement of Principles will change how factors are interpreted under s11.

The instrument does not specify transitional provisions governing claims that were lodged but not finalised at the date of repeal of the 2013 Statement, nor does it state whether the new Statement applies retrospectively or only to claims made after commencement. Those transitional effects are therefore governed by the application provisions of the VEA, MRCA, or administrative practice, not by this Statement itself. The only explicit temporal markers contained in this instrument are its date, its commencement date, and the repeal of the prior named Statement (s1-s4).

For users tracking legislative history, this instrument should be read as replacing the earlier 2013 Statement as of 20 September 2021, with the text and definitions provided in this instrument governing the medical assessment of polycythaemia vera and related death for claims within the statutory scope described in s5. Any further amendments to this Statement would need to be located in subsequently made Statements or registers; the current text contains no further amendment entries.

The text of this Statement contains no litigation history and names no judicial decisions. It records the Repatriation Medical Authority’s view that there is sound medical‑scientific evidence supporting a relationship between polycythaemia vera and relevant service (s8), but it does not summarise any cases, appeals or tribunal decisions. The instrument is a medical statement intended to be applied in the statutory claims processes set out in the VEA and MRCA (s5), and any litigation that occurs in relation to claims invoking this Statement will be recorded in external judicial or tribunal records rather than in the Statement itself.

Because the Statement operates as a medical standard under subsection 196B(2) of the VEA (s3), disputes about its application are procedural and evidentiary questions within claim processes. The Statement does not set out appeal mechanisms or note prior litigation outcomes. It is therefore silent on the extent to which courts or tribunals have interpreted the Statement or its predecessor Statement No. 11 of 2013. The repeal of the 2013 Statement is recorded (s4), but the instrument does not describe any litigated issues that may have prompted the replacement.

Users seeking litigation history must therefore consult tribunal and court records arising from VEA or MRCA claims where polycythaemia vera was in issue. This Statement should be treated as the current medical framework for reasonable hypothesis assessment from its commencement date (s2). Where a decision maker, tribunal or court is required to determine whether a reasonable hypothesis exists in a particular claim, that adjudicator will apply the statutory definition in s7, the factors in s9, and the relationship to service rules in s10. Any judicial or tribunal interpretation of those provisions will be external to, and not recorded in, this instrument.

In sum, the Statement itself provides no case law citations, no account of prior litigation, and no analysis of how courts or tribunals have treated the earlier or current Statement. It is a medical‑scientific instrument to be applied inside the statutory claim framework; litigation history must be sourced from the decisions in the VEA and MRCA administrative and judicial appeal pathways rather than from the Statement’s text.

The instrument contains a number of detailed textual points that can trip up claim preparation and decision making if overlooked. These are matters of statutory wording and definitional detail that materially affect whether a reasonable hypothesis is raised.

1. Definition overrides ICD‑10-AM code: Although subsection 7(3) notes that polycythaemia vera attracts ICD‑10‑AM code D45, the instrument insists the meaning of polycythaemia vera for applying the Statement is the statutory definition in s7(2). Practitioners should not rely solely on an ICD code; the clinical presentation must meet the statutory elements (s7(2)-(4)).

2. Exclusions in the definition: The statutory definition expressly excludes relative polycythaemia, familial and congenital polycythaemia, and secondary polycythaemia from hypoxaemia or increased erythropoietin (s7(2)(c)(i)-(iii)). If a claimant’s condition falls into any of these excluded categories, the Statement’s factors and pathway will not apply.

3. Masked or bled down included: The Statement explicitly includes masked or bled down polycythaemia vera (s7(2)(b)). Where standard laboratory values are reduced by treatment or haemodilution, evidence must still address whether the disease falls within the statutory meaning.

4. Smoking factor timing and calculation: Section 9(1) has three temporal and exposure requirements: at least 10 pack‑years before clinical onset; smoking commencing at least five years before clinical onset; and if smoking ceased before onset, onset must have been within 15 years of cessation. The Schedule defines a pack‑year and gives weight equivalents and calculation examples (Schedule 1). Errors often arise from misuse of pack‑year calculations or failure to establish the timing relative to clinical onset (s9(1), Schedule 1).

5. Management factor scope: The inability to obtain appropriate clinical management (s9(2)) is available only for material contribution to, or aggravation of, polycythaemia vera where the disease was suffered or contracted before or during (but did not arise out of) relevant service (s10(2)). This means a claimant whose polycythaemia vera arose out of service cannot, under this Statement, rely on s9(2) to establish causation; s9(2) is confined to contribution/aggravation in pre‑existing or service‑onset but non‑service‑arising disease.

6. Relationship to service requirement: Any factor in s9 must be related to relevant service per s10(1). The instrument does not specify how to prove that relationship; claimants must connect the factor (for example, smoking history or lack of clinical management) to the particular type of relevant service as defined in the Schedule (Schedule 1).

7. Cross‑referenced Statements: If a factor in s9 refers to a disease covered by another Statement of Principles, the other Statement’s factors apply as in force from time to time (s11). The operative content of such cross‑references can change if the other Statement is amended or repealed.

8. Death definition extends to terminal events: Death from polycythaemia vera includes deaths where a terminal event or condition was contributed to by the person’s polycythaemia vera (s7(5)). The Schedule defines “terminal event” in a list of proximate causes such as pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function (Schedule 1). Therefore, death certificates citing those proximate causes may still fall within this Statement if evidence shows contribution by polycythaemia vera.

9. No procedural or evidential guidance: The instrument establishes medical thresholds but does not provide procedural guidance on how evidence should be collected, weighed, or presented in claims. Claimants and advisers must therefore ensure evidence addresses the statutory elements precisely, since the Statement itself does not explain evidential standards.

10. Repeal of prior Statement: This Statement repealed Statement No. 11 of 2013 (s4). Practitioners should check which Statement was current at the time of the claimant’s lodgement or relevant decisions, as the applicable medical criteria changed as of the commencement date (s2). The instrument does not set transitional rules.

Each of these is grounded in the statutory text. Overlooking any of them can change whether the Statement’s criteria are met, and therefore whether a reasonable hypothesis has been raised linking polycythaemia vera or death from it to relevant service.

Compliance here means preparing and presenting evidence in a way that engages the statutory tests the Statement sets out. The Statement does not create administrative procedures itself, but it establishes definite elements that must be evidenced for a reasonable hypothesis to be found. Practical steps for claimants, advisers, and medical assessors, drawn from the instrument’s text, are below.

1. Establish the statutory diagnosis. Confirm the condition meets the definition in s7(2). Medical reports should record whether the disease is a chronic Philadelphia‑chromosome negative myeloproliferative neoplasm with elevated red cell production and any excess of platelets and white blood cells, or whether the presentation is masked or bled down (s7(2)(a)-(b)). If the claimant’s condition is relative, familial or congenital polycythaemia, or secondary polycythaemia from hypoxaemia or increased erythropoietin, the Statement does not apply (s7(2)(c)(i)-(iii)).

2. Document clinical onset. For the smoking factor, establish the date of clinical onset of polycythaemia vera, because s9(1) requires temporal relationships to be measured relative to onset. Clinical records should identify the earliest medical evidence of disease, symptoms or laboratory abnormalities consistent with the statutory definition (s9(1), s7).

3. Quantify tobacco exposure precisely. Use the Schedule’s pack‑year definition and calculation method. Determine number of cigarettes per day, divide by 20, multiply by years smoked, and convert non‑cigarette tobacco by weight if necessary (Schedule 1). Demonstrate at least 10 pack‑years and that smoking commenced at least five years before clinical onset. If smoking ceased before onset, show onset occurred within 15 years of cessation (s9(1), Schedule 1).

4. If relying on management factor, gather evidence on availability of care. For s9(2), document the clinical management that was appropriate for polycythaemia vera at the relevant time and why it was unavailable. Because s10(2) restricts s9(2) to material contribution or aggravation where the disease was suffered or contracted before or during (but did not arise out of) relevant service, evidence must show the disease pre‑dated service or began during service but did not arise out of it, and that lack of appropriate management materially contributed to or aggravated the disease (s9(2), s10(2)).

5. Tie factors to relevant service. Section 10(1) requires that any factor in s9 be related to the person’s relevant service. Evidence should therefore connect the smoking history or lack of management to the claimant’s service record, and specify which type of “relevant service” applies as defined in the Schedule (operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, or warlike/non‑warlike service under the MRCA) (Schedule 1, s10(1)).

6. Address death causation where relevant. If the claim is for death from polycythaemia vera, prepare evidence showing that polycythaemia vera contributed to the terminal event or condition listed in the Schedule, such as pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function (s7(5), Schedule 1). Medical evidence should link the disease to the proximate cause(s) of death set out on the death certificate.

7. Check cross‑referenced Statements. If any factor invoked in a claim refers to another disease covered by a different Statement of Principles, consult the current text of that other Statement because s11 makes that Statement’s factors applicable as in force from time to time (s11).

8. Prepare comprehensive medico‑legal reports. Reports should map facts and clinical findings to the statutory text: diagnosis per s7(2), smoking exposure and timing per s9(1) and Schedule 1, management availability per s9(2) and s10(2), and the relationship to relevant service per s10(1). Avoid relying solely on ICD coding; the Statement’s statutory definition controls (s7(3)-(4)).

9. Maintain documentary service evidence. Because the Statement requires linking factors to relevant service types defined in the Schedule, ensure service records, postings, and dates are available to show when and what type of service was rendered (Schedule 1).

10. Be aware of temporal applicability. The current Statement commenced on 20 September 2021 (s2) and repealed the 2013 Statement (s4). If a claim spans the repeal date or if earlier decisions relied on the prior Statement, confirm which Statement applied for the relevant decision or time period.

Following these steps aligns evidence with the precise statutory elements of the Statement, enabling decision makers administering the VEA or MRCA to assess whether a reasonable hypothesis has been raised that polycythaemia vera or death from polycythaemia vera is connected to relevant service.